The catalyst: the build is finished, and the cash it was eating is about to come back

For four years, EBOS Group has been pouring money into warehouses. Recently in August 2026 the trans-Tasman healthcare distributor told investors that phase is done. The A$360 million distribution-centre renewal program — the largest infrastructure Investment in the company’s history — is complete, and Capital Expenditure is set to fall to roughly A$100 million in FY27 from the elevated levels of recent years. Management paired that with FY27 underlying EBITDA guidance of A$635 million to A$655 million, above the A$614 million just reported. The market read it as the moment the Earnings drag broke: the ASX- and NZX-listed shares jumped more than 8 per cent on the day, to about A$19.73. The story is no longer about spending; it is about harvesting.

 

What just happened

EBOS Group (ASX:EBO) reported Revenue of A$13.5 billion for the year to 30 June 2026, up 9.9 per cent. Underlying EBITDA rose 5.0 per cent to A$614 million. Underlying net profit after tax slipped 3.1 per cent to A$250 million, weighed down by the Depreciation and financing costs that flow from the new facilities. Reported NPAT, which strips out one-off items differently, rose 4.7 per cent to A$225 million.

The centrepiece asset is the Kemps Creek distribution centre in western Sydney, which replaced the older Greystanes site. Management said Kemps Creek is already running about 20 per cent more productively than its predecessor, and is targeting a 30 per cent gain by the end of FY27 as volumes ramp. That productivity Dividend is the payoff the whole program was designed to deliver.

The directors held the final dividend at NZ 61.5 cents per share, matching the prior year, payable in September 2026. The payout represents roughly 84.5 per cent of underlying NPAT.

 

Why it matters

EBOS is a Business most Australians and New Zealanders touch without noticing — it moves medicines to pharmacies and hospitals, supplies pet-food and animal-health brands, and distributes medical devices. Scale distribution is a low-margin, high-volume game where a few points of Warehouse efficiency translate into real money. The FY26 result matters because it marks the pivot from a capital-hungry phase, which suppressed free Cash Flow and profit, to one where the Assets should convert Volume into cash more cleanly. Management flagged that free cash flow is expected to improve meaningfully in FY27 as capital intensity normalises.

 

The numbers that matter

Revenue A$13.5 billion (+9.9 per cent). Underlying EBITDA A$614 million (+5.0 per cent), an underlying EBITDA Margin near 4.6 per cent — slim, and slightly lower year on year, which is the nature of distribution. Underlying NPAT A$250 million (-3.1 per cent); underlying Earnings Per Share 121.7 cents (-7.3 per cent). Return on capital employed 12.8 per cent, down 20 basis points. Leverage sat at 2.1 times, inside the company’s 1.7-to-2.3-times target band, with roughly A$726 million of undrawn committed facilities. Capital deployed across the year was about A$400 million, including the tail of the A$360 million warehouse program and A$121 million on eight bolt-on acquisitions.

 

The bigger industry picture

EBOS straddles three structurally growing markets. Healthcare distribution — its Symbion pharmaceutical wholesaling and hospital-supply arm — generated A$12.6 billion of revenue (+8.5 per cent) and A$516 million of EBITDA (+3.2 per cent). It is a defensive, ageing-population business, but a thin-margin one exposed to government pricing policy and pharmacy competition.

Animal care was the standout, with revenue up 34.6 per cent to A$907 million and EBITDA up 11.6 per cent to A$138 million, lifted by acquisitions such as Paringa Pet Foods. Pet spending has proved sticky, and the segment carries fatter margins than drug wholesaling.

Medical technology — devices and consumables sold into hospitals — grew revenue about 5.5 per cent, or 8.4 per cent on a constant-currency basis. Management said more than 70 per cent of group EBITDA now comes from these higher-growth, higher-return businesses, a deliberate shift away from pure wholesaling.

 

The bull case

The investment cycle has crested. If Kemps Creek and the other renewed sites deliver the promised productivity, EBOS should widen margins on flat capital spending — the ideal operating-leverage set-up. The FY27 guidance implies about 5 per cent EBITDA growth at the midpoint, and management says it assumes no new acquisitions, leaving deals as upside; it flagged roughly A$150 million of balance-sheet capacity for further bolt-ons. The portfolio tilt toward animal care and medical technology lifts the group’s blended growth and return profile, and 85 per cent of EBITDA now comes from businesses ranked first or second in their markets. A maintained dividend and leverage inside target signal balance-sheet comfort.

 

The risks

Distribution margins are wafer-thin, so cost shocks bite: management called out fuel-price volatility, a strong Australian dollar crimping offshore earnings, and persistent community-pharmacy competition. The New Zealand wholesale contract with Chemist Warehouse is scheduled to roll off at the end of calendar 2026, an impact management sized at mid-to-high single-digit millions of EBITDA, or about 1 per cent of the group — a reminder of contract concentration after the far larger Australian Chemist Warehouse arrangement exited in FY25. Underlying NPAT and EPS still fell this year; the recovery is a forecast, not yet a fact. And the productivity targets for Kemps Creek must actually materialise to justify the spend.

 

What happens next

Watch these markers. First, whether FY27 lands inside the A$635–655 million EBITDA range, with earnings weighted to the second half. Second, free-cash-flow conversion as capex drops toward A$100 million — the clearest proof the build is paying off. Third, the Kemps Creek productivity climb toward 30 per cent. Fourth, the clean exit of the Chemist Warehouse New Zealand contract at year-end and how much it actually costs. Fifth, bolt-on Acquisition activity in animal care and medical technology, where the group has firepower and stated appetite.

 

Conclusion

EBOS has spent four years and A$360 million rebuilding the plumbing of its distribution network, and FY26 is the year that spending stopped rising and the bill started coming due in depreciation. That is why Underlying Profit dipped even as revenue pushed toward A$13.5 billion. The investment thesis from here is simpler than it has been in some time: fixed assets, falling capex, and a management team pointing to more cash and modestly higher earnings in FY27. The share-price jump suggests investors are willing to believe the harvest is coming. The proof will be in next year’s cash flow and in whether those gleaming new warehouses run as efficiently as promised. For now, EBOS has cleared its biggest build — and bought itself a cleaner story.